AIS's Health Business Daily is a daily email newsletter with strategic business stories written by experienced AIS Health reporters, as well as other information of interest to health care business leaders — including news from the nation’s leading health insurers, developments from the federal and state governments that impact the health care industry, and exclusive datapoints from Subscribe now to get an issue delivered to your inbox every morning!
February 7, 2017

Hot Topic

This week all eyes are on the Affordable Care Act’s health insurance exchanges, which logged lower enrollment compared to last year as Congress debates an ACA repeal. Here’s a look at AIS’s recent coverage on the topic:

Some SBEs Report Double-Digit Enrollment Gains for 2017
Health Plan Week

As Deadline Nears to Ensure Jan. 1 Start, SBEs Expect Surge
Health Plan Week

2017 Outlook: Blues Plan CEOs Look to 2017 With Mix of Hope, Concern About Health Care Reform
The AIS Report on Blue Cross and Blue Shield Plans*

* Not affiliated with the Blue Cross and Blue Shield Association or its member companies.

American Well
Today's AIS Health Datapoint

34% ... of pharmacy benefit policies cover Jardiance as a preferred drug. The diabetes medication from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Co. is subject to step-therapy protocols on 41% of plans, and prior authorization requirements on 24% of plans.

Click here to read the DRUG BENEFIT NEWS article in which this datapoint appeared — "Agreement Will Leverage Data to Support Outcomes-Based Contracts" (Free for DBN subscribers; $17 for non-subscribers.)


Quote of the Day

The pricing scheme for kaléo insulin autoinjector Auvi-Q “is grotesque because it is likely to become a lightning rod for justifiable criticism of the United States’ laissez-faire approach to prescription pharmaceutical pricing. Renewed focus on this, soon after the Mylan Epi-Pen pricing debacle, could negatively impact the sustainability of our current pharmaceutical pricing and reimbursement, particularly in light of the new administration’s attitude” that prices for pharmaceuticals are too high.

— Elan Rubinstein, Pharm.D., principal at EB Rubinstein Associates, tells Drug Benefit News.

Click here to read the DRUG BENEFIT NEWS article in which this quote appeared — "Auvi-Q Prepares to Launch at Zero Cost to Most Patients, but Payers Footing the Bill" (Free for DBN subscribers; $17 for non-subscribers.)


Advertise with AISThe Featured Story of the day may be accessed on the day it is transmitted without logging in to Thereafter, you may need to log in to access the Featured Story. If you haven’t yet registered on, please take a minute to create a free account now and get free access to thousands of articles, blogs and much more.

Content questions or suggestions should be directed to Executive Editor Jill Brown at If you are interested in advertising in AIS's HEALTH BUSINESS DAILY, please contact BJ Taylor at

AIS's HEALTH BUSINESS DAILY is copyrighted and protected by federal law. The re-use of its content is restricted (see below). However, you are permitted to forward this email to as many of your friends and colleagues as you wish, or better yet have them sign up for their own copy at atlantic_subscription.cfm

Copyright © 2017 Managed Markets Insight & Technology, LLC. All rights reserved. It is not permissible to include all or any portion of this content on any Web site, intranet or electronic network or in any print publication, without AIS's written permission in advance. Permission requests should be directed to

With archives of AIS's Health Business Daily, features like the News Archives, AIS Blogs and more! (Free registration required)

Visit AISHealth on: AISHealth  Follow AISHealth on Twitter  Follow AISHealth on Facebook  Follow AISHealth on LinkedIn